Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping
epidemiology of prevalence, health care costs and social costs in quality of life. Both are …

Over 20 million adults and 6 million children in the United States (US) have asthma, a
chronic respiratory disease characterized by airway inflammation, bronchoconstriction, and …

Background Asthma is a heterogeneous disease. Clinical blood parameters differ by
race/ethnicity and are used to distinguish asthma subtypes and inform therapies. Differences …

Omalizumab has demonstrated efficacy among patients with moderate to severe persistent
allergic asthma, whose symptoms are inadequately controlled with other controller agents …

Background Omalizumab (OMA) is an effective anti-immunoglobulin E (IgE) treatment for
moderate-to-severe asthma. However, predicting an individual's response is difficult …

BACKGROUND: The Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical
Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma (EXCELS) …

Abstract Background Immunoglobulin E (IgE) is the treatment target of omalizumab, a
monoclonal antibody indicated in the treatment of severe allergic asthma. Long-term …

Asthma is a common disease in the worldwide and it affects over 3.5 million adults and
children in the UK. Asthma is a chronic disease characterized by airway …

Billy, who is 2 years old, presents to the physician's office with his fourth episode of
wheezing in the past 18 months. He was admitted to hospital at 6 months of age with …

Omalizumab, a monoclonal antibody that targets circulating IgE, is approved as add-on
therapy for adult and adolescent patients with severe allergic asthma in the EU and …